GCT1184-02: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer

Objective

Clinical Trial Details

IRB Protocol Number

2024.069

Principal Investigator(s)

David Starks, MD

Clinical Trial Categories

• Cancer
• Gynecologic Cancer

Contact

Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org